完整後設資料紀錄
DC 欄位語言
dc.contributor.authorChou, Po-Hanen_US
dc.contributor.authorChu, Che-Shengen_US
dc.contributor.authorChen, Yi-Hueien_US
dc.contributor.authorHsu, Min-Yenen_US
dc.contributor.authorHuang, Min-Weien_US
dc.contributor.authorLan, Tsuo-Hungen_US
dc.contributor.authorLin, Ching-Hengen_US
dc.date.accessioned2018-08-21T05:54:02Z-
dc.date.available2018-08-21T05:54:02Z-
dc.date.issued2017-06-01en_US
dc.identifier.issn0165-0327en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.jad.2017.03.044en_US
dc.identifier.urihttp://hdl.handle.net/11536/145502-
dc.description.abstractBackground: Previous studies demonstrated increased risk of cataract development among users of selective serotonin reuptake inhibitors (SSRIs). However, it remains unknown whether this risk also prevails with the use of other types of antidepressants. The aim of this study was to investigate whether use of antidepressants is associated with an increased risk of cataract development. Moreover, the relationship between binding affinities of serotonin transporter (SERT) of antidepressant and the risk of cataracts is examined. Methods: We conducted a nested case-control study using National Health Insurance Research Database in Taiwan. A total of 14,288 patients were included; 7651 in the cataract group and 6637 in the control group. Antidepressant exposure was categorized by type, duration of use, and binding affinities of SERT. The association between antidepressant exposure and cataract development was assessed using conditional logistic regression analysis. Results: The adjusted odds ratios (AORs) for developing cataracts among continuous users of SSRIs, serotonin norepinephrine reuptake inhibitors (SNRIs), and other antidepressants were 1.26 (95% confidence interval (CI): 1.12-1.41, p < 0.001), 1.21 (95% CI: 1.02-1.43, p=0.027), and 1.18 (95% CI: 1.04-1.34, p=0.009) respectively. Specifically, continuous uses of fluoxetine (AOR: 1.21; 95% CI: 1.01-1.46, p=0.042), fluvoxamine (AOR: 1.47; 95% CI: 1.01-2.12, p=0.043), venlafaxine (AOR: 1.44; 95% CI: 1.19-1.74, p < 0.001) significantly increased the risk of cataract development. Moreover, continuous users of antidepressants with intermediate SERT binding affinities (AOR: 1.68; 95% CI: 1.10-2.56, p=0.017) were significantly associated with increased risks of cataract development. Limitations: Several confounding factors such as obesity, multiple drug users, family history of cataracts, substance use, and environmental factors (such as sunlight or radiation exposure) were acquired. Conclusions: We found increased risk of cataract development in patients continuously using antidepressants. Regular ocular evaluations in these patients are warranted.en_US
dc.language.isoen_USen_US
dc.subjectAntidepressantsen_US
dc.subjectCataracten_US
dc.subjectSelective serotonin reuptake inhibitoren_US
dc.subjectSerotonin norepinephrine reuptake inhibitorsen_US
dc.titleAntidepressants and risk of cataract development: A population-based, nested case-control studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jad.2017.03.044en_US
dc.identifier.journalJOURNAL OF AFFECTIVE DISORDERSen_US
dc.citation.volume215en_US
dc.citation.spage237en_US
dc.citation.epage244en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.department光電工程學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.contributor.departmentDepartment of Photonicsen_US
dc.identifier.wosnumberWOS:000401213300033en_US
顯示於類別:期刊論文